- Home
- CON vs DNLI Comparison
CON vs DNLI Comparison
Compare CON & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CON
- DNLI
- Stock Information
- Founded
- CON 1979
- DNLI 2013
- Country
- CON United States
- DNLI United States
- Employees
- CON N/A
- DNLI N/A
- Industry
- CON
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CON
- DNLI Health Care
- Exchange
- CON NYSE
- DNLI Nasdaq
- Market Cap
- CON 2.9B
- DNLI 3.1B
- IPO Year
- CON 2024
- DNLI 2017
- Fundamental
- Price
- CON $22.90
- DNLI $18.84
- Analyst Decision
- CON Strong Buy
- DNLI Strong Buy
- Analyst Count
- CON 7
- DNLI 13
- Target Price
- CON $28.86
- DNLI $37.91
- AVG Volume (30 Days)
- CON 701.3K
- DNLI 822.8K
- Earning Date
- CON 03-03-2025
- DNLI 03-11-2025
- Dividend Yield
- CON 0.27%
- DNLI N/A
- EPS Growth
- CON 0.28
- DNLI N/A
- EPS
- CON 1.59
- DNLI N/A
- Revenue
- CON $1,875,891,000.00
- DNLI N/A
- Revenue This Year
- CON $4.40
- DNLI N/A
- Revenue Next Year
- CON $8.03
- DNLI $289.18
- P/E Ratio
- CON $14.37
- DNLI N/A
- Revenue Growth
- CON 8.79
- DNLI 204.74
- 52 Week Low
- CON $18.89
- DNLI $14.56
- 52 Week High
- CON $24.81
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- CON N/A
- DNLI 37.23
- Support Level
- CON N/A
- DNLI $18.67
- Resistance Level
- CON N/A
- DNLI $22.81
- Average True Range (ATR)
- CON 0.00
- DNLI 1.15
- MACD
- CON 0.00
- DNLI -0.29
- Stochastic Oscillator
- CON 0.00
- DNLI 14.42
About CON CONCENTRA GROUP HOLDINGS PARENT INC
Concentra Group Holdings Parent Inc is a company providing occupational and consumer health services through occupational health centers and onsite clinics. Their services include workers' compensation injury care, employer services, urgent care, clinical testing, wellness programs, and preventative care.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.